ATE306498T1 - Von zellen präsentierte peptide - Google Patents

Von zellen präsentierte peptide

Info

Publication number
ATE306498T1
ATE306498T1 AT01962874T AT01962874T ATE306498T1 AT E306498 T1 ATE306498 T1 AT E306498T1 AT 01962874 T AT01962874 T AT 01962874T AT 01962874 T AT01962874 T AT 01962874T AT E306498 T1 ATE306498 T1 AT E306498T1
Authority
AT
Austria
Prior art keywords
peptides
cells
determination
peptides presented
relates
Prior art date
Application number
AT01962874T
Other languages
English (en)
Inventor
Francis J Carr
Graham Carter
Koen Hellendoorn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE306498T1 publication Critical patent/ATE306498T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01962874T 2000-08-03 2001-07-26 Von zellen präsentierte peptide ATE306498T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0018901.9A GB0018901D0 (en) 2000-08-03 2000-08-03 Peptides presented by cells
PCT/EP2001/008625 WO2002012899A2 (en) 2000-08-03 2001-07-26 Peptides presented by cells

Publications (1)

Publication Number Publication Date
ATE306498T1 true ATE306498T1 (de) 2005-10-15

Family

ID=9896790

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01962874T ATE306498T1 (de) 2000-08-03 2001-07-26 Von zellen präsentierte peptide

Country Status (20)

Country Link
US (1) US20030171290A1 (de)
EP (1) EP1305343B1 (de)
JP (1) JP2004506202A (de)
KR (1) KR20030037272A (de)
CN (1) CN1511164A (de)
AT (1) ATE306498T1 (de)
AU (1) AU2001283958A1 (de)
BR (1) BR0112925A (de)
CA (1) CA2417767A1 (de)
CZ (1) CZ2003464A3 (de)
DE (1) DE60114018T2 (de)
GB (1) GB0018901D0 (de)
HU (1) HUP0301581A2 (de)
MX (1) MXPA03000901A (de)
NO (1) NO20030495L (de)
PL (1) PL358874A1 (de)
RU (1) RU2003105806A (de)
SK (1) SK1982003A3 (de)
WO (1) WO2002012899A2 (de)
ZA (1) ZA200301637B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020094530A1 (en) * 2000-09-18 2002-07-18 Nicolette Charles A. Method to identify antibody targets
WO2002103360A1 (fr) * 2001-06-19 2002-12-27 Suntory Limited Methode d'analyse d'une proteine apparaissant dans une cellule ou d'une substance interagissant avec la proteine
CA2537900A1 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
US20090061478A1 (en) * 2006-01-30 2009-03-05 Lene Have Poulsen High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465B1 (de) 2007-07-03 2025-02-19 Dako Denmark A/S Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
CA2778552A1 (en) 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Treatment of cancer involving mutated kras or braf genes
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
AU2014266833B2 (en) * 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
ES2970865T3 (es) * 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
AU2017335084B2 (en) * 2016-09-30 2023-06-29 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
EP4576103A3 (de) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigenidentifizierung mit hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0983303B1 (de) * 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6468537B1 (en) * 1999-04-28 2002-10-22 The Board Of Trustees Of Northwestern University Localization of major peptide autoepitopes for nucleosome specific T cells of systemic lupus erythematosus

Also Published As

Publication number Publication date
JP2004506202A (ja) 2004-02-26
ZA200301637B (en) 2004-02-03
CN1511164A (zh) 2004-07-07
EP1305343B1 (de) 2005-10-12
CZ2003464A3 (cs) 2003-06-18
WO2002012899A2 (en) 2002-02-14
AU2001283958A1 (en) 2002-02-18
BR0112925A (pt) 2003-08-26
PL358874A1 (en) 2004-08-23
DE60114018T2 (de) 2006-06-29
CA2417767A1 (en) 2002-02-14
NO20030495D0 (no) 2003-01-31
GB0018901D0 (en) 2000-09-20
KR20030037272A (ko) 2003-05-12
EP1305343A2 (de) 2003-05-02
MXPA03000901A (es) 2003-06-24
SK1982003A3 (en) 2003-08-05
NO20030495L (no) 2003-01-31
DE60114018D1 (de) 2006-02-23
US20030171290A1 (en) 2003-09-11
RU2003105806A (ru) 2004-07-20
HUP0301581A2 (hu) 2003-08-28
WO2002012899A3 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
ATE306498T1 (de) Von zellen präsentierte peptide
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
BR0211199A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
ATE499382T1 (de) Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
CY1105282T1 (el) Διαγνωση της κοιλιοκακης με τη χρηση ενος επιτοπιου της γλιαδινης
WO2002002783A3 (en) Expression vectors
WO2004024750A3 (en) Cd44-binding ligands
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
WO2006069203A3 (en) Methods for proteomic profiling using non-natural amino acids
ATE363070T1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
BR9815788A (pt) Proteìna quimérica, ácido nucleico isolado, célula recombinante, processos para produzir uma proteìna quimérica, e para obter uma proteìna quimérica, produto, e, ensaio para triar uma sequência amino ácida quanto à capacidade de melhorar a dobragem de um precusor de insulina
WO2001053531A3 (en) Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AUPR775401A0 (en) Novel Epitopes and Uses Thereof
SE9701228D0 (sv) Rekombinanta protein-C-och protein-S-varianter
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
WO2003082897A3 (en) Synthetic active peptide fragments
DE60308176D1 (de) Vorrichtung von peptid- oder proteindarstellung, verfahren zu deren herstellung und deren verwendung
DE69631624D1 (de) Antikörper gegen menschliches restrictin
WO2003099209A3 (en) Compositions and methods for screening and identifying anti-hcv agents
WO2003025197A3 (en) Mutant sh3-binding protein compositions and methods

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties